GlassScriptPhysician profile
Trish E Dauphin
NPI 1740831916
$3,489.06
in general payments reported to CMS, 2019-2025
27 companies · $1,470 in 2025
The $1,470 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $623 · 2022: $483 · 2023: $437 · 2024: $475 · 2025: $1,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,382.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $697.07 | 2021-2025 | Epclusa, Yeztugo |
| Viiv Healthcare Company | $366.16 | 2021-2025 | Cabenuva, Apretude, Rukobia |
| Genzyme Corporation | $245.82 | 2021-2025 | |
| Alkermes, INC. | $229.67 | 2021-2025 | Aristada, Vivitrol, Lybalvi |
| Boston Scientific Corporation | $166.60 | 2022 | |
| Dexcom, INC. | $163.44 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Exact Sciences Corporation | $150.99 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $134.07 | 2024 | Aptima |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2022 | |
| Edwards Lifesciences Corporation | $125.00 | 2025 | |
| Lilly USA, LLC | $122.50 | 2025 | Mounjaro |
| Scilex Pharmaceuticals INC. | $121.09 | 2021-2023 | Ztlido |
| Alexion Pharmaceuticals, INC. | $113.71 | 2022 | |
| Agile Therapeutics, INC. | $111.36 | 2021 | |
| Abbvie INC. | $101.12 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $97.46 | 2021 | |
| Merck Sharp & Dohme LLC | $80.18 | 2023-2025 | Pifeltro, Delstrigo, Capvaxive |
| Janssen Pharmaceuticals, INC | $55.61 | 2024-2025 | Invega |
| Braeburn INC. | $44.07 | 2024-2025 | Brixadi |
| Theratechnologies INC. | $41.87 | 2024 | Trogarzo, Egrifta |
| Otsuka America Pharmaceutical, INC. | $34.50 | 2025 | Rexulti |
| Janssen Biotech, INC. | $33.26 | 2023 | Symtuza |
| Neurocrine Biosciences, INC. | $29.78 | 2023 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $28.34 | 2025 | Qelbree |
| Novartis Pharmaceuticals Corporation | $27.82 | 2024 | |
| Emd Serono, INC. | $22.42 | 2025 | |
| Corium, LLC | $20.15 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trish Dauphin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.